High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.

Journal of cancer research and clinical oncology 2023 Jul

filter terms:

Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer. 225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS). High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival. Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future. © 2022. The Author(s).

Citation

Susanne Beyer, Lena Müller, Sophie Mitter, Lucia Keilmann, Sarah Meister, Christina Buschmann, Fabian Kraus, Nicole E Topalov, Bastian Czogalla, Fabian Trillsch, Alexander Burges, Sven Mahner, Elisa Schmoeckel, Sanja Löb, Stefanie Corradini, Mirjana Kessler, Udo Jeschke, Thomas Kolben. High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer. Journal of cancer research and clinical oncology. 2023 Jul;149(8):4293-4303